These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
10. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Levine B Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450 [TBL] [Abstract][Full Text] [Related]
11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome: treatment of hypertensive patients. Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215 [TBL] [Abstract][Full Text] [Related]
13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
14. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment]. Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399 [TBL] [Abstract][Full Text] [Related]
15. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. White WB Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448 [TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
17. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Deedwania PC Cardiol Clin; 2005 May; 23(2):139-52. PubMed ID: 15694743 [TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
19. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Tytus RH; Burgess ED; Assouline L; Vanjaka A Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockade in the challenging era of systolic hypertension. Stergiou GS J Hum Hypertens; 2004 Dec; 18(12):837-47. PubMed ID: 15318161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]